Navigation Links
Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
Date:5/28/2009

nt plans, the potential safety and efficacy of its products in development and commercialization strategy. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of clinical testing; the receipt and timing of FDA and other required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Report on Form 10-Q for the period ended March 31, 2009, which was filed with the SEC on May 11, 2009. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.

(1) American Cancer Society, Cancer Facts and Figures 2008


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
2. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
3. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
4. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
5. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
6. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
7. Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
8. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
9. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
10. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
11. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , October 31, 2014 ... clinical-stage pharmaceutical company focused on the development of ... will host a conference call to discuss the ... of ORMD-0801, the company,s proprietary oral insulin capsules, ... 3, 2014 at 10:00 a.m. Eastern time. ...
(Date:10/31/2014)... October 31, 2014 Investor-Edge has ... NSPH ), Isis Pharmaceuticals Inc. (NASDAQ: ... HALO ), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ... on these five companies can be accessed at: ... the NASDAQ Composite ended at 4,566.14, up 0.37%, the ...
(Date:10/31/2014)... California , November 3, 2014 ... need for men with BPH to discuss "male orgasmic ... system shows ability to treat prostate symptoms while preserving ... Inc., today welcomes the publication of a paper in ... men suffering from enlarged prostate to discuss with their ...
Breaking Medicine Technology:Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 2Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 3Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 4Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma 5Sexual Dysfunction No Longer Inevitable When Treating Enlarged Prostate 2
... (NYSE: LLY ) announced Phase I data on ... (BAFF), for use in combination with bortezomib in patients with ... be presented on Sunday, June 5 at 11:30 a.m. CDT ... (Abstract #8012) at the 47th Annual Meeting of the American ...
... May 19, 2011 Perceptive Informatics , the ... PAREXEL International Corporation (NASDAQ: PRXL ), today ... webinar entitled "Critical Tasks of Site Monitors: Using a ... industry professionals across a broad range of clinical, data ...
Cached Medicine Technology:Study Determined Best Dose and Showed 55 Percent Response Rate With Lilly Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients 2Study Determined Best Dose and Showed 55 Percent Response Rate With Lilly Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients 3Study Determined Best Dose and Showed 55 Percent Response Rate With Lilly Anti-BAFF Monoclonal Antibody in Previously-Treated Multiple Myeloma Patients 4Perceptive Informatics® Global Survey Results Indicate Growing Demand for CTMS to Assist in More Efficient Site Monitoring and Management 2Perceptive Informatics® Global Survey Results Indicate Growing Demand for CTMS to Assist in More Efficient Site Monitoring and Management 3Perceptive Informatics® Global Survey Results Indicate Growing Demand for CTMS to Assist in More Efficient Site Monitoring and Management 4Perceptive Informatics® Global Survey Results Indicate Growing Demand for CTMS to Assist in More Efficient Site Monitoring and Management 5
(Date:10/31/2014)... 2014 Monica Williams-Murphy MD , ... too well the chaos that can occur for people ... vast majority of Americans who come into the emergency ... completely unprepared for the moment and so are their ... serve as a catalyst for a family to get ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 Energy Textiles ... gear. The new gear is now available online, and ... the benefits of Celliant infrared-active athletic gear over compression ... that another contract has been signed for Under Armour ... for the next eight years. In light of this ...
(Date:10/31/2014)... insomnia is a major contributor to deaths caused by ... results underscore the importance of the "Sleep Well, Be ... , Results show that the risk of unintentional fatal ... of insomnia symptoms present. People with all three symptoms ... from a fatal injury than those with no insomnia ...
(Date:10/31/2014)... North Shore Eye Care today announced the ... and the addition of leading ophthalmologist, William S. Kasper, ... Shore Eye Care Medical Director, Jeffrey Martin, MD. , ... Department of Ophthalmology of Winthrop-University Hospital and has maintained ... more than 30 years. He has been named to ...
(Date:10/31/2014)... 2014 In an effort to expand services ... Jamali announced he will soon offer orthodontics at his Oral ... of November. , To build upon the high degree ... York has become known for, Dr. Jamali is welcoming an ... top learning institutions as UCLA, Stanford and UCSF. He added ...
Breaking Medicine News(10 mins):Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 2Health News:This Thanksgiving or Christmas Family Gathering, Use The New App ListStuffFast to Start "The Conversation" With a Parent That Has No Plan For End-of-Life 3Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 2Health News:William Kasper, MD Garden City Ophthalmologist, Joins Medical Staff at North Shore Eye Care 3Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 2Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 3
... Nov. 14 For the sixth consecutive,year, VSP Vision ... World Class Customer Satisfaction Award from Service Quality,Measurement Group, ... in the past two years,we have added over two ... President of Customer Service Laura Costa. "We also had ...
... Through the implementation,of its best management practices (BMPs), ... protecting the environment, the ADA told Congress today., ... have had a very positive,impact," said Dr. J. ... the House Oversight and Government Reform Committee,s,domestic policy ...
... key mechanism in how bacteria communicate with each other, a ... other bacterial diseases. , The mechanism is a chemical ... known as CAI-1, and has been isolated in the lab ... the chemical also can be used to disrupt the communication ...
... Grill & Bar, other partners and donors share ... into the new National,Pediatric Brain Tumor Consortium headquarters, ... learning in,translational research for exceptional patient care, ... Hospital(R) and Chili,s Grill & Bar(R) celebrated the ...
... Nov. 14 Transcept,Pharmaceuticals, Inc. today announced that ... Officer, will present at the 19th Annual,Piper Jaffray ... New York City,on Tuesday, November 27, 2007 at ... Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical ...
... 50-State Disability Rights Bus Tour and Traveling Exhibit,Returns ... Senator Tom Harkin and,other members of Congress will ... back The Road To Freedom: Keeping the Promise ... cross-country bus tour,and traveling exhibit promoting the civil ...
Cached Medicine News:Health News:VSP Vision Care Recognized for World Class Customer Satisfaction 2Health News:ADA Outlines Successful Environmental Efforts 2Health News:Princeton scientists break cholera's lines of communication 2Health News:Princeton scientists break cholera's lines of communication 3Health News:St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chili's Care Center 2Health News:St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chili's Care Center 3Health News:St. Jude Celebrates Next Frontier of Finding Cures With Grand Opening of Chili's Care Center 4Health News:Members of Congress and Disability Rights Advocates Support the Restoration of the Americans with Disabilities Act and Welcome Back the Road To Freedom Bus 2Health News:Members of Congress and Disability Rights Advocates Support the Restoration of the Americans with Disabilities Act and Welcome Back the Road To Freedom Bus 3
... refrigerated floor-standing centrifuge. Mobile space saver, ... choice of accessories, analog controls, large ... shutdown (JOUAN patented pendulum system), guard ... temperature limitation, rugged motor, tough steel ...
... refrigerated bench-top centrifuge. Very ... large choice of accessories, ... true sample temperature control, ... true RCF, informative display, ...
Powerful refrigerated bench-top centrifuge. Very powerful, high capacity rotors, large choice of accessories, heat labile sample protection, guard barrier, dual lid interlock, easy to use, variable c...
GP8RF is a powerful 3-liter ventilated centrifuge which is flexible, easy to use and fit on, beside or below the lab bench. Performs separations 50-100% faster than the rest, powerful, accommodating ...
Medicine Products: